预约演示

更新于：2025-07-15

Spironolactone

螺内酯

更新于：2025-07-15

概要

基本信息

简介螺内酯，也称为ALDACTONE®，是一种盐皮质激素受体（MR）拮抗剂。它由辉瑞公司于1960年在美国首次获批。口服片含有25毫克、50毫克或100毫克的螺内酯，其特异性药理学拮抗剂作用于醛固酮。螺内酯通过竞争性结合肾小管远曲小管内醛固酮依赖性钠钾交换位点的受体，主要作用于此，导致钠和水的排泄增加，而钾则保留。史比洛克通适用于心力衰竭、高血压、肝硬化或肾病综合征相关的水肿以及原发性醛固酮增多症。它作为利尿剂和降压药物，可以单独或与其他更靠近肾小管的利尿剂联合使用。

药物类型

小分子化药

别名

Spironolactone (JP17/USP/INN)、Spironolattone、NSC-150399

+ [8]

靶点

作用方式

拮抗剂

作用机制

MR拮抗剂(盐皮质激素受体拮抗剂)

治疗领域

神经系统疾病心血管疾病消化系统疾病+ [3]

在研适应症

心肌梗塞脑卒中肾病综合征+ [8]

非在研适应症-

原研机构

G.D. Searle & Co., Inc.

在研机构

Pfizer Japan, Inc.Nova Laboratories Ireland Ltd.CMP Development LLC

+ [1]

非在研机构

CMP Pharma, Inc.

国药集团武汉中联四药药业有限公司

权益机构-

最高研发阶段批准上市

首次获批日期

美国 (1960-01-21),

腹水水肿原发性高血压+ [4]

最高研发阶段(中国)撤市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C24H32O4S

InChIKeyLXMSZDCAJNLERA-ZHYRCANASA-N

CAS号52-01-7

关联

336

项与螺内酯相关的临床试验

NCT07041281

/ Not yet recruiting临床2期IIT

Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories

The hypertensive disorders of pregnancy (preeclampsia and gestational hypertension) are associated with increased long-term maternal risk of developing cardiovascular disease. Recent evidence suggests that activation of the mineralocorticoid receptor promotes ongoing susceptibility to hypertension in women following hypertensive disorders of pregnancy. In addition, women with overweight/obesity are at increased risk for progression to chronic hypertension after experiencing hypertensive disorders of pregnancy. Among women with hypertensive disorders of pregnancy and pre-pregnancy overweight/obesity, the investigators will conduct a randomized trial to test the effect of pharmacologically blocking the mineralocorticoid receptor for three months after delivery on blood pressure and cardiac remodeling at nine months postpartum.

开始日期2025-09-02

申办/合作机构

The Massachusetts General Hospital

[+2]

NCT07015671

/ Recruiting临床3期

Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Subjects

This study examines the bioavailability and bioequivalence of single dose of a Fixed Dose Combination (FDC) tablet (12 mg Extended-Release Torsemide and 15mg Spironolactone). The goal of this study is to determine PK/PD effects of the FDC, 10 mg Torsemide alone, 25mg Aldactone® (Spironolactone) alone, and 10 mg Torsemide and 25 mg Aldactone® (Spironolactone) taken together in healthy subjects.

开始日期2025-07-01

申办/合作机构

Sarfez Pharmaceuticals, Inc.

NCT07043634

/ Recruiting临床3期

An Open Label, Randomized, Two-period, Two-sequence, Balanced, Single Dose Crossover Study to Evaluate the Effect of Food on the Bioavailability of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Human Subjects

This study will examine comparative bioavailability of single dose of a fixed dose combination (FDC) of extended release Torsemide and Spironolactone given with or without food in healthy adult subjects.

开始日期2025-06-15

申办/合作机构

Sarfez Pharmaceuticals, Inc.

100 项与螺内酯相关的临床结果

登录后查看更多信息

100 项与螺内酯相关的转化医学

登录后查看更多信息

100 项与螺内酯相关的专利（医药）

登录后查看更多信息

11,636

项与螺内酯相关的文献（医药）

2025-10-01·AMERICAN JOURNAL OF OPHTHALMOLOGY

Eplerenone and Spironolactone for Chronic Central Serous Chorioretinopathy: A Systematic Review and Meta-Analysis

Review

作者: Sarraf, David ; Benour, Ali ; Huang, Ryan S ; Kertes, Peter J ; Kohly, Radha P ; Zaman, Michele ; Sadda, SriniVas R ; Mihalache, Andrew ; Muni, Rajeev H ; Popovic, Marko M

TOPIC:

To evaluate the efficacy and safety of mineralocorticoid receptor antagonists (MRAs), specifically eplerenone and spironolactone, in comparison to observation, photodynamic therapy (PDT), and subthreshold micropulse laser (SML) for chronic central serous chorioretinopathy (cCSCR).

CLINICAL RELEVANCE:

In the context of cCSCR, MRAs are thought to reduce choroidal vascular hyperpermeability and thickness by inhibiting the mineralocorticoid receptor pathways that contribute to fluid accumulation.

METHODS:

A systematic literature search was performed using Ovid MEDLINE, Embase, and the Cochrane Library from January 2000 to March 2024 for comparative studies evaluating the efficacy of MRAs against other treatment arms for cCSCR. The primary outcome was the best-corrected visual acuity (BCVA) at the last study visit, as well as at specific follow-up timepoints (ie, 1 month, 3 months, 6 months, 12 months). Secondary outcomes included retinal thickness (RT), subretinal fluid (SRF) height, and SRF resolution at the same timepoints. Meta-analyses were performed using a random-effects model, with subgroup analyses performed for eplerenone and spironolactone separately. A P-value of less than 0.05 was considered statistically significant.

RESULTS:

Thirteen articles (four RCTs reporting on 253 eyes and nine observational studies reporting on 393 eyes, mean follow-up duration = 7.02 ± 3.78 months) were included. The mean BCVA at the last study visit was similar between the MRA and observation groups (WMD=-0.01 logMAR, 95% CI = [-0.05, 0.02], P = .40, n = 5 studies). However, MRAs resulted in a significantly lower mean SRF height at 1 month (WMD=-69.56 µm, 95% CI [-127.26, -11.86], P = .02, n = 2 studies), while the observation group had a significantly lower SRF height at 12 months (WMD=48.23 µm, 95% CI [45.99, 50.46], P < .00001, n = 2 studies). Similarly, MRAs demonstrated a higher rate of SRF resolution at 1 month (RR=4.24, 95% CI = [1.54, 11.72], P = .005), whereas the observation group showed a higher resolution rate at 12 months (RR=0.45, 95% CI = [0.22, 0.95], P = .04). On subgroup analysis, spironolactone showed a significantly reduced mean RT at the last study visit compared to observation (WMD = -46.44 µm, 95% CI [-74.76, -18.13], P = .001, n = 2 studies). When compared to PDT, MRAs were associated with a significantly higher mean SRF height at the last study visit (WMD = 51.99 µm, 95% CI [2.70, 101.27], P = .04, n = 2 studies). In contrast, efficacy outcomes were largely similar between patients treated with MRAs and SML at the last study visit, with no significant differences in SRF resolution (P = .22, n = 2 studies).

CONCLUSION:

MRAs offer short-term benefits in reducing SRF but may have limited long-term durability based on current evidence, highlighting the need for further studies.

2025-10-01·JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Evaluation of reference ranges of four circulating sex steroids from dried blood spots in women aged 18-40 years

Article

作者: Desai, Reena ; Davis, Susan R ; Wang, Yuanyuan ; Gialouris, Josh ; Handelsman, David J

Capillary dried blood spot collection offers an excellent less invasive alternative to serum or plasma collection by venesection. This study aimed to generate reference ranges for four sex steroids in capillary whole blood samples collected from healthy premenopausal women as dried blood spots as a screening method to detect disorders of sex development. Using this method we evaluated variations according to age, body mass index, menstrual cycle, and hormonal contraceptive use. This cross-sectional, community-based study included 120 healthy premenopausal women aged 18-40 years, not pregnant or breastfeeding. Whole blood testosterone (T), androstenedione (A4), 17α hydroxyprogesterone (17OHP), and progesterone (P4) were measured by liquid chromatography-tandem mass spectrometry (LCMS) from dried filter paper blood spots. The median (95 % confidence limits) for T were 0.75 (0.28, 2.20) nmol/L, A4 2.69 (1.02, 6.03) nmol/L, 17OHP 1.62 (0.32, 8.52) nmol/L and P4 0.65 (0.18, 41.0) nmol/L. Age by 5-year interval was associated with a progressive reduction in A4 but not for other steroids. Menstrual variation was evident for 17OHP and P4 with increases in luteal phase with a small mid-cycle peak for A4 but no other consistent changes. All sex steroid concentrations were significantly lower in participants taking a systemic hormonal contraceptive (combined oral contraceptive or etonogestrel implant). None of the sex steroid concentrations varied significantly with body mass index. These data provide reference ranges for whole blood T, A4, 17OHP and P4 measured by LCMS from dried blood spots from healthy young adult premenopausal women. Small but significant variations were evident according to age, hormonal contraceptive use and menstrual cycle phase.

2025-09-01·EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Optimization and stability evaluation of a pediatric spironolactone oral suspension: Formulation development and analytical validation

Article

作者: Brouillet, Fabien ; Jamme, Thibaut ; Verdier, Céline ; Jaafar, Acil ; Lanot, Thomas ; Cavalie, Laurent ; Cavalie, Sandrine ; Ramjaun, Zoubeir ; Jurado, Camille ; Chagneau, Camille ; Metsu, David ; Desquines, Roxanne

The pediatric population often faces challenges in accessing appropriate medication formulations, particularly for circumstances like congenital heart disease requiring spironolactone therapy. This study aimed to optimize the pharmaceutical formulation of oral suspension spironolactone for pediatric use and assess its stability. A formulation with 0.2 % xanthan gum in InOrpha® was developed, showing improved stability and reduced sedimentation. Analytical method validation confirmed accuracy and precision for spironolactone quantification, while forced degradation studies ensured stability-indicating capability. Stability assessments demonstrated the oral suspension's chemical, physical, and microbiological stability for up to 135 days pre-bottle opening and 37 days post-opening under varied storage conditions. This study provides crucial insights into enhancing spironolactone formulation for pediatric patients. Further research is needed to assess pharmacokinetic parameters such as bioavailability and pharmacodynamics to fully ascertain its efficacy in pediatric populations.

109

项与螺内酯相关的新闻（医药）

10 小时之前

·医学新视点

华山医院包丽雯：高血压合并糖尿病，优选这5类药物！

重点凝练高血压合并糖尿病并不是一道“加法题”，而是一道“乘法题”。高血压合并糖尿病患者的治疗，选择具有心血管以及肾脏保护作用的降压药物十分重要，如血管紧张素转换酶抑制剂及血管紧张素受体阻滞剂、盐皮质激素受体拮抗剂等。高血压及糖尿病是发生心血管疾病（CVD）的2个重要独立危险因素。当患者同时存在糖尿病合并高血压，他们发生CVD的风险及全因死亡风险比仅有糖尿病或仅有高血压的患者成倍增加，需要引起我们更多的重视及积极的干预。糖尿病患者容易出现高血压流行病学调查研究表明，患有胰岛素抵抗与糖尿病的患者不仅会出现以肥胖为代表的代谢异常，也更易出现高血压、动脉硬化。在2型糖尿病的队列研究及随机对照研究中，我们不难发现，其中约70%左右患者合并存在高血压；然而，在高血压的临床研究中，合并存在2型糖尿病的比例约为30%~50%。在李勇教授牵头的中国多中心横断面研究UPPDATE的数据分析中，在高血压患者中，合并糖尿病的比例大约为20.38%。由此，我们推测在2型糖尿病中，以胰岛素抵抗为代表的一系列病理生理变化会对高血压发生、发展产生深远影响，也有专家提出糖尿病性高血压这一定义。因此，本论述将主要从糖尿病性高血压的可能机制及糖尿病合并高血压的推荐治疗手段这两个方面入手，对高血压与糖尿病的cross-talk进行阐述。我们主要关注2型糖尿病。糖尿病性高血压的可能机制Framingham Offspring研究曾在1933例基线无高血压的患者中，观察胰岛素抵抗与高血压发生、发展的关系，在4年随访期间，即使调整了体重指数（BMI）增加这一混杂效应，胰岛素抵抗与高血压发生、发展也呈显著正相关。4701例参与者的队列研究发现，糖耐量受损和2型糖尿病人群发生动脉硬化的风险远高于血糖正常者，而胰岛素抵抗通过增加动脉僵硬度，进一步导致高血压及CVD发生。由此可见，以胰岛素抵抗为核心的病理生理改变是糖尿病性高血压的主要发生机制。▲胰岛素抵抗或为糖尿病性高血压的主要病理生理机制① RAAS过度激活体内和体外的观察研究发现，胰岛素抵抗会诱导RAAS过度激活，使得血管阻力及动脉压力增加；RAAS过度激活也可以通过损伤胰岛素信号通路影响血压。血管紧张素Ⅱ及醛固酮水平的上调会增加丝氨酸磷酸化水平，使得P13K通路活性下降，导致内皮细胞一氧化氮合成与激活能力降低，抑制一氧化氮介导的血管舒张作用。此外，激活的RAAS通过上调SGK-1通路，增加血管内皮钠离子通道（EnNaC）的活性，促进动脉硬化与高血压发生、发展。在临床研究中，我们发现在糖尿病人群中使用AT-1受体阻滞剂和盐皮质激素受体拮抗剂可以降低糖尿病患者高血压的发病率。▲RAAS激活可通过多途径影响动脉硬化及血压② 线粒体功能异常与过度的氧化应激线粒体生物合成障碍、自噬能力降低、线粒体产能下降等线粒体功能异常是2型糖尿病的主要病理生理改变之一，其所导致的内皮细胞功能异常是高血压发生、发展的主要原因。此外，NADPH氧化酶激活也是过量氧化应激产物（ROS）产生的重要来源，胰岛素抵抗可诱导血管内NADPH氧化酶激活，后者导致过量ROS生成，促使内皮衍生-舒张因子和内皮衍生-收缩因子失衡，使得血管张力增加，过量的ROS也会通过减少NO产生，促进动脉硬化和高血压发生、发展。因此，线粒体功能障碍和氧化应激是胰岛素抵抗和糖尿病状态下高血压发生、发展的重要机制之一。糖尿病合并高血压的推荐治疗手段如前所述，高血压与糖尿病是CVD的重要病因，选择具有心血管以及肾脏保护作用的降压药物十分重要。目前，各临床指南一致推荐，应当使用血管紧张素转换酶抑制剂及血管紧张素受体阻滞剂作为糖尿病患者合并高血压的一线用药。对于糖尿病合并存在难治性高血压患者，建议加用盐皮质激素受体拮抗剂（螺内酯、非奈利酮、依普利酮），此类药物被证实可以显著降低合并存在肾功能不全的2型糖尿病患者的心衰风险及肾功能进一步恶化风险。GLP-1受体激动剂（GLP1-RA）及钠-葡萄糖共转运蛋白2抑制剂（SGLT2i）可以显著降低2型糖尿病患者的心肾事件风险及全因死亡风险。临床研究也发现，这两类药物具有降低2型糖尿病患者血压的作用。GLP-1RA的降压作用猜测与其减重作用相关，SGLT2i的降压作用可能与排钠、排糖、生酮等作用相关，作为口服药物，SGLT2i在降压领域的研究比较全面。关于SGLT2i的荟萃分析一项荟萃分析发现，在2型糖尿病合并高血压和高血压前期的患者中，SGLT2i具有显著的降压疗效。这项荟萃分析纳入了2450例患者，与使用安慰剂相比，使用SGLT2i者其收缩压及舒张压（诊室血压）降幅分别为5.04 mmHg（95%CI：-3.79~-6.30，P＜0.01）和1.67 mmHg（95%CI：-2.45~-0.89，P＜0.01），其中恩格列净的降压幅度最大，并且其降压效果随着药物剂量的增加而增加。此项荟萃分析还对SGLT2i对血压变异度的影响做了相关研究。研究人员分析发现，SGLT2i降低平均日间收缩压的幅度（-4.57 mmHg，95%CI：-3.71~-5.43，P＜0.01）大于降低平均夜间收缩压的幅度（-2.8 mmHg，95%CI：-1.84~-3.76，P＜0.01）。此外，在亚组分析中，发现达格列净5 mg qd治疗14天，可以将血压从非杓型转变为杓型血压，但由于样本缺失，分析病例较少，尚不能形成可靠结论。关于恩格列净的RCT为了研究恩格列净在合并高血压的2型糖尿病患者中的降压效果，Hans团队进行了一项随机对照研究，证实了恩格列净在此人群中的显著降压效果。研究纳入825例患者，随机给予安慰剂、恩格列净10 mg及恩格列净25 mg，通过24小时动态血压监测观察恩格列净的降压效果。在随访的12周末，与安慰剂相比，10 mg恩格列净组的平均收缩压降幅为-3.34 mmHg，（95%CI：-4.78~-2.09mmHg，P＜0.001），25 mg恩格列净组的平均收缩压降幅为-4.16 mmHg（95%CI：-5.5~-2.83mmHg，P＜0.001)。▲恩格列净在研究中的降压幅度，恩格列净10 mg及25 mg 可以显著降低平均收缩压及舒张压小结由此，我们不难发现，高血压合并糖尿病并不是一道“加法题”，而是一道“乘法题”。在我们理解了两者合并带来了更多的心肾风险，以及糖尿病性高血压以“胰岛素抵抗为中心”可能机制后，在高血压合并糖尿病患者中，我们应当采用临床证据更加充分的药物——血管紧张素转换酶抑制剂及血管紧张素受体阻滞剂、盐皮质激素受体拮抗剂、SGLT2i、GLP1-RA，来管理这部分患者，以期获得更好的心肾保护作用。作者简介包丽雯复旦大学附属华山医院心内科副主任医师医学博士中国医学救援队队员华山医院内科学上海市住院医生规范化培训基地秘书中国高血压联盟理事，长三角心血管急重症联盟委员，中国微循环学会基层慢病管理委员会委员推荐阅读JAMA：治疗高血压，一针管半年！长效RNAi降压疗法联合用药，额外降压12 mmHg心血管死亡风险激增197%！最新研究发现，高血压合并糖尿病危害大，女性更需注意JAMA：强效降压近14 mmHg，66%患者血压达标！这种难治性高血压治疗药物值得关注站起来血压就升高？BMJ：强化降压有益于降低直立性高血压风险，无糖尿病获益更大全球13亿高血压患者新希望？新研究：降压潜在新选择，值得临床关注免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。分享，点赞，在看，传递医学新知

临床研究

22 小时之前

·梅斯医学

原发性醛固酮增多症治疗新突破！NEJM：Baxdrostat的精准靶向机制与12周降压疗效解析

原发性醛固酮增多症（Primary Aldosteronism, PA）是继发性高血压的重要原因之一，其特征为醛固酮分泌过多，导致钠潴留和钾流失，进而引发高血压及低钾血症。尽管现有药物如螺内酯能一定程度缓解病情，但疗效有限，且副作用影响患者依从性。传统的醛固酮合成酶抑制剂因作用不够选择性，常伴随皮质醇合成受抑及前体物质积累等问题，限制了其广泛应用。此外，PA患者中多数病例非单纯单侧病变，手术治疗效果有限，药物治疗需求迫切。新一代选择性醛固酮合成酶抑制剂如Baxdrostat，有望直接靶向致病机制，实现更精准有效的治疗。7月13日，《新英格兰医学杂志》（The New England Journal of Medicine, NEJM）发表了一项关于Baxdrostat在PA患者中应用的IIa期临床研究成果。该多中心、开放标签、前瞻性研究，招募了15例基于内分泌学会指南确诊的患者，探讨Baxdrostat作为一种高选择性醛固酮合成酶抑制剂在临床上的安全性及降压疗效。研究结果显示，经过12周的治疗，患者的收缩压平均下降约24.9 mmHg，且低钾血症得到有效纠正。长期随访（最长达72周）中，药物的疗效持续稳定，安全性良好。这为原发性醛固酮增多症治疗领域带来了新的突破。研究结果分析1.患者基本特征共纳入15例患者，平均收缩压151.5±13.5 mmHg，舒张压90.3±8.8 mmHg。2.收缩压及舒张压变化治疗12周后，所有患者均显示收缩压降低，平均下降24.9 mmHg（95% CI，19.0-30.8）。舒张压平均下降10.6±9.0 mmHg。73%的患者达到目标血压＜140/90 mmHg。3.电解质及ARR变化5例低钾血症患者均获得纠正。醛固酮-肾素比值显著减少，中位下降97.3%（四分位距84.3%-98.9%），14例患者ARR达临床靶值＜15（93%，95% CI，68-100）。血浆和24小时尿醛固酮水平分别降低约90.9%及91.6%（95% CI分别为73.9-92.9%和89.6-94.3%）。4.肾素活性及激素水平血浆肾素活性逐渐回升，12周时增加约1.8倍，至72周增加约6.0倍（95% CI，2.0-16.3）。血清11-脱氧皮质酮水平于治疗8周峰值上升11.5倍，此后逐渐下降至治疗36周时降幅约50%。血浆皮质醇水平保持平稳，12周时稍有增加，但未见明显低皮质醇血症。5.安全性及肾功能治疗期间未出现严重不良事件，部分接受8 mg剂量的患者在长期治疗中出现估计肾小球滤过率短暂下降，停药后恢复至基线水平。1例患者发生严重高钾血症与合并复杂疾病相关。总体药物耐受性良好。6.长期疗效维持进入延长期的14名患者中，降压和醛固酮抑制效果维持稳定。停药后肾功能恢复，且血压控制和生化指标持续改善。图：Baxdrostat治疗前后相关指标变化及长期随访趋势图综上，本研究报道了一种高度选择性的醛固酮合成酶抑制剂Baxdrostat在PA患者中的疗效，尤其显著且持久的降压效果，为临床治疗提供了新的药物选择。由于PA患者体内醛固酮过高直接加重钠潴留及高血压，靶向抑制醛固酮合成是治疗根本。与传统抗矿物质皮质激素药物（如螺内酯）相比，Baxdrostat作用更精准，对皮质醇影响小，副作用减少，提升患者治疗依从性。此外，长期数据提示药物的安全性较良好，能够维持血压和电解质稳定，特别是在难治性高血压患者中有较大潜力推向临床应用。研究也强调PA患者多为双侧病变，单纯手术治疗效果有限，药物治疗需求亟待满足。该研究为PA的个体化和精准治疗奠定了基础，也支持将选择性醛固酮合成酶抑制剂作为PA治疗的未来方向。原始出处：Turcu AF, Freeman MW, Bancos I, et al. Phase 2a Study of Baxdrostat in Primary Aldosteronism. N Engl J Med. 2025 Jul 13;(online ahead of print). DOI: 10.1056/NEJMc2508629.撰文 | 梅斯头条编辑 | 木白●热议！凌晨1点去急诊换药，医生果断拒绝：换药非急症，不要占用资源！家属嫌陪护床太硬，竟睡在了医生休息室，医患之间要有边界感●人均每天刷短视频2.6小时！它正在“吃掉”你的大脑？多项研究：短视频不仅影响心理健康，还改变大脑功能● 外科分15%，行政后勤却高达20%，医院绩效惹争议！湖南三甲整顿行政：要摆正位置，你们是为临床服务的！三明医改新变化，医生躺不平版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

临床结果临床2期

2025-07-10

·PRNewswire

Shed Launches Medical-Grade Hair Solutions for Men and Women

SALT LAKE CITY, July 10, 2025 /PRNewswire/ -- Shed, a modern wellness company focused on helping individuals feel and function their best, announces the launch of its new Hair Solutions vertical—a complete line of medical-grade oral and topical treatments designed to address the real biological drivers of hair thinning and loss. Continue Reading Formulas Target the Root Causes of Hair Loss with Personalized, Prescription-Based Care "Most hair loss treatments on the market focus on surface-level fixes," said Shed CEO Morley Baker at Shed. "We built these solutions to address the root causes—hormonal imbalance, inflammation, poor circulation, and nutrient delivery—using prescription-grade, science-backed ingredients personalized for each user." Shed's new product line includes combination oral capsules and high-potency topical solutions that work synergistically to reduce DHT, calm inflammation, stimulate follicles, and support the natural hair growth cycle. Formulas are tailored to the unique needs of men and women, including those experiencing genetic hair loss, hormonal shifts, postpartum shedding, or stress-induced fallout. For men, the lineup features multi-ingredient oral tablets and comprehensive topicals that combine Finasteride, Minoxidil, Tretinoin, and other proven actives to support scalp health and regrowth. Women's solutions include oral capsules with Spironolactone and Minoxidil, along with advanced topicals and a copper peptide option for those seeking gentle yet effective support. Whether early-stage shedding or long-term thinning, Shed's approach is rooted in multi-pathway intervention—not one-size-fits-all promises. By offering prescription access through a seamless telehealth model, Shed ensures users receive treatment that is not only powerful but also safe, accessible, and tailored to individual needs. About Shed Shed is redefining modern wellness with personalized, science-backed solutions designed to help people feel and function at their best. As a leader in personalized health, Shed offers cutting-edge treatments tailored to the unique needs of each individual—supporting longevity, boosting energy, improving sleep, and enhancing metabolic health. Shed believes health is a journey, not a destination, and empowers individuals to take control of their well-being—to feel well, live well, and thrive every day. Media Contact: Jamie Neider 801-520-5785 [email protected] SOURCE Shed WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与螺内酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00443	螺内酯	C03DA01	DB00421

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心肌梗塞	美国	CMP Development LLC	2017-08-04
脑卒中	美国	CMP Development LLC	2017-08-04
肾病综合征	美国	Pfizer Inc.	1981-06-30
高血压	日本	Pfizer Japan, Inc.	1965-03-30
腹水	美国	Pfizer Inc.	1960-01-21
水肿	美国	Pfizer Inc.	1960-01-21
原发性高血压	美国	Pfizer Inc.	1960-01-21
心脏衰竭	美国	Pfizer Inc.	1960-01-21
醛固酮增多症	美国	Pfizer Inc.	1960-01-21
低钾血症	美国	Pfizer Inc.	1960-01-21
肝硬化	美国	Pfizer Inc.	1960-01-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04676646 (REALIZE-K, CTgov)	临床4期	射血分数降低的心力衰竭 \| 高钾血症	366	Placebo+Spironolactone+Sodium zirconium cyclosilicate	積願築鑰範願範願範膚(餘繭鑰鏇廠襯製觸願窪) = 餘蓋醖鬱襯範鬱顧糧齋鹹願觸醖衊窪網鏇壓醖 (淵鑰艱鏇繭醖餘鬱蓋鏇, 衊餘壓鑰壓壓鑰窪醖淵 ~ 夢遞獵鬱糧鏇製醖壓鹹) 更多	-	2025-07-09
ATS2025	N/A	早产儿疾病	-	Furosemide	顧夢積憲網齋簾築繭觸(鏇襯淵選餘廠繭繭鑰醖) = 鹹襯繭糧窪範製鏇餘選糧衊願衊淵製鹹獵糧遞 (繭繭顧遞願襯醖鹽觸鏇 ) 更多	-	2025-05-16
				Chlorothiazide	顧夢積憲網齋簾築繭觸(鏇襯淵選餘廠繭繭鑰醖) = 餘鏇網淵鏇膚選鏇鬱網糧衊願衊淵製鹹獵糧遞 (繭繭顧遞願襯醖鹽觸鏇 ) 更多
NCT03576755 (CTgov)	临床1/2期	非酒精性脂肪性肝炎	20	Spironolactone 100mg (Spironolactone)	積夢廠齋襯襯築範製壓(廠觸淵獵觸積選鑰構範) = 夢鹽簾積襯壓餘鏇鹹簾鏇鏇願窪淵觸鏇壓壓顧 (膚遞鑰艱膚簾窪壓繭鹽, 顧夢鑰遞膚簾構網齋獵 ~ 齋顧選遞膚遞餘鹹醖艱) 更多	-	2025-03-26
				Placebo oral capsule (Placebo)	積夢廠齋襯襯築範製壓(廠觸淵獵觸積選鑰構範) = 鏇襯顧衊廠獵壓製醖範鏇鏇願窪淵觸鏇壓壓顧 (膚遞鑰艱膚簾窪壓繭鹽, 夢襯選鏇顧願衊醖鑰鑰 ~ 遞築艱選壓廠憲襯艱製) 更多
NCT04283656 (IDENTIFY, CTgov)	临床1期	HIV感染	8	Spironolactone 100mg+Estradiol 2mg+Doravirine/Lamivudine/Tenofovir (Treatment C)	廠遞壓選窪願廠顧顧窪(窪範艱夢範築艱壓淵齋) = 範淵衊鬱淵顧鏇構範衊膚鏇蓋廠淵顧淵糧獵簾 (鬱鑰繭鑰範淵構夢壓築, 21.7) 更多	-	2025-03-26
				Doravirine/Lamivudine/Tenofovir (Treatment A)	廠遞壓選窪願廠顧顧窪(窪範艱夢範築艱壓淵齋) = 積憲範觸積築構齋製網膚鏇蓋廠淵顧淵糧獵簾 (鬱鑰繭鑰範淵構夢壓築, 41.75) 更多
NCT05010707 (TREAT, CTgov)	临床2期	-	39	Hormone Profile+Spironolactone+Transdermal patch (Transdermal Estradiol Plus Spironolactone)	簾遞艱選顧鹹憲製觸憲(廠遞鬱淵齋餘簾獵壓鬱) = 襯構齋衊醖鏇壓鏇構顧鹽簾糧網選鹽蓋網範餘 (簾構鬱鏇窪淵構鑰醖願, 46.2) 更多	-	2024-11-26
				Hormone Profile+Spironolactone+Daily Sublingual Tablet (Daily Sublingual Estradiol Plus Spironolactone)	簾遞艱選顧鹹憲製觸憲(廠遞鬱淵齋餘簾獵壓鬱) = 獵積遞蓋憲襯築窪積醖鹽簾糧網選鹽蓋網範餘 (簾構鬱鏇窪淵構鑰醖願, 61.3) 更多
NCT04676646 (REALIZE-K, Pubmed \| J Am Coll Cardiol)	临床4期	高钾血症	203	Sodium Zirconium Cyclosilicate (SZC)	獵窪製築憲獵齋蓋遞鬱(艱鏇製衊積鹽選遞衊構) = 願襯膚蓋鬱選鏇構憲網鏇繭糧憲壓憲膚鏇衊築 (築遞膚餘艱選製製壓襯 )	积极	2024-11-01
				Placebo	獵窪製築憲獵齋蓋遞鬱(艱鏇製衊積鹽選遞衊構) = 鏇餘遞網積選鏇蓋築顧鏇繭糧憲壓憲膚鏇衊築 (築遞膚餘艱選製製壓襯 )
ESC2024	N/A	心脏衰竭 \| 室性心动过速维持	405	Spironolactone	艱夢簾壓遞壓膚淵蓋鹹(觸齋襯願選簾鬱鹽觸壓): HR = 0.59, P-Value = 0.023	积极	2024-09-02
				Eplerenone
ESC2024	N/A	-	-	Spironolactone 25-50 mg/d	觸獵鏇糧夢膚選鹹繭獵(鬱餘鹽糧範鹹鑰餘製齋) = from 21.3 to 18.3 觸觸製獵膚淵艱願鏇選 (製齋醖遞鏇積遞襯艱糧 ) 更多	-	2024-08-30
				Usual therapy
NCT02169089 (MAGMA, Pubmed \| Circulation) 人工标引	临床4期	2型糖尿病 \| 慢性肾病	79	Spironolactone 25 mg	襯鹽鏇衊製醖獵積廠鹹(鑰築網選遞範壓鹹獵襯) = 範鹽願艱選選鏇鏇觸鹽範鏇積築網觸顧鏇糧壓 (鹽鹹憲獵鬱衊淵築廠鏇, 10.0) 更多	积极	2024-08-27
				Placebo	襯鹽鏇衊製醖獵積廠鹹(鑰築網選遞範壓鹹獵襯) = 衊鏇網積鬱鹹鏇鑰積顧範鏇積築網觸顧鏇糧壓 (鹽鹹憲獵鬱衊淵築廠鏇, 10.7) 更多
NCT00094302 (TOPCAT, ESC2024)	临床3期	射血分数保留型心力衰竭 serum creatinine	-	Spironolactone	簾範網範製廠製廠獵鹹(獵艱糧網鏇製顧鹽獵積) = 衊選窪廠糧觸鑰構憲觸襯膚獵顧選鏇製築顧襯 (鏇積顧繭鏇艱糧憲鹽遞 )	积极	2024-05-13
				Placebo	簾範網範製廠製廠獵鹹(獵艱糧網鏇製顧鹽獵積) = 膚襯蓋齋網鹹淵範餘糧襯膚獵顧選鏇製築顧襯 (鏇積顧繭鏇艱糧憲鹽遞 )